Defensive Underweight with catalyst-paced trim — trim 25-33% on rally into $70.57 resistance, not at market
This is defensive Underweight with catalyst-paced trim, not a directional bet. The income thesis is intact and real but does not justify adding at an unconfirmed pivot. The technical setup is genuinely weak but not broken. Trim 25-33% on rally into resistance — not at market, not at stop distance, not on magnitude-overshoot terms. Capture the dividend carry at sub-benchmark defensive sizing (75% of benchmark or 2-3% of portfolio for income holders) while waiting for either breakout confirmation to add back or structural break to exit fully.
| Position | Action |
|---|---|
| Income-holder sizing | Cap at 2-3% of portfolio |
| New entries | Stay sidelined at current levels |
| Add back to neutral | 75% sub-benchmark on confirmed daily close >$70.57 on volume >7M with MACD line turning positive AND RSI >55 sustained |
| Add on pullback | To $66.98 (20 SMA) or $65.00 (200 SMA) zone with stabilization (higher low, declining volume) |
| Trim magnitude | Capped at 25-33% of MO weighting |
| Capitulation exit | Daily close <$60 on volume >15M |
Altria's structural pricing power, dominant margins, and $9B in annual FCF make it a cash-generation machine mispriced as a declining business, with the technical breakout and macro backdrop now confirming the bull case.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 65.00 (rising) | bullish |
| 50 SMA | 69.97 (flattening) | neutral |
| 10 EMA | 68.35 (rising) | bullish |
| RSI (14) | 54.96 | neutral |
| MACD Line | -0.09 | neutral |
| MACD Signal | -0.63 | neutral |
| MACD Histogram | +0.54 (rising) | bullish |
| Bollinger Upper Band | $70.57 | neutral |
| Bollinger Middle Band (20 SMA) | $66.98 | neutral |
| Bollinger Lower Band | $63.39 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $70.02 stall for 2+ sessions with weakening momentum
Then: Trim 25-33% of MO weighting
Despite revenue decline, Altria's pricing power drives margin expansion and gross profit growth
EV: $73.79 (primary); $77.06 (extension) · concedes: Bear has legitimate point on secular cigarette volume decline (4–5% annually); Negative stockholders' equity is a real accounting fact, even if misleading as a risk signal; Payout ratio vs. net income (89%) is elevated, though FCF coverage (79%) is more relevant; on! brand concentration is a real smoke-free strategy risk; MO is up 95% over 5 years, limiting near-term upside
Altria faces structural decline in core cigarette volumes, regulatory headwinds from FDA hostility, failed M&A with $1.158B impairments, and a dividend yield trap with 79% FCF payout ratio and PEG of 2.67 — the stock offers no margin of safety.
EV: -8% to -16% · concedes: The 61 dividend increases in 57 years is impressive; The AB InBev stake exists at ~$5+/share; The July 30 gap-down did retrace 50%; RSI is not oversold (neutral at 54.96)
→ vs conservative: MACD 'still negative' is lagging indicator complaint; MACD line follows price which has already recovered; waiting for MACD line to go positive before buying means missing the move
→ vs conservative: Flat 50 SMA at $69.97 is healthy consolidation in uptrend, not breakdown; 200 SMA at $65 and rising confirms golden cross structure intact
→ vs conservative: Selling right before Bollinger upper band is textbook mistake of selling right before expansion; ATR compression signals breakout not breakdown
→ vs conservative: Margin compression from 55% to 49.1% from one-time non-cash items ($2.7B sale, $652M boost); cannot make structural bearish case from non-recurring charge already taken
→ vs conservative: NJOY impairment already priced in at July 30 gap down; selling now is selling the news two months late after 30 trading days of retracement
→ vs conservative: FCF coverage is 79% of FCF not 89% of net income; conservative coverage not stretched as bear case claims
→ vs conservative: 11.85x forward earnings with 19% growth and 6%+ yield is discount not premium as bear case implies
→ vs conservative: FDA litigation is offensive (accelerating pipeline) not defensive (de-risking); Trefis smoke-free critique already in the multiple
| ATR (14) | 1.65 | neutral |
| Current Price | $69.56 (2026-09-02) | neutral |
| Crash Low | $63.96 (2026-08-17) | neutral |
Support: 68.35 · 66.98 · 65 · 63.39 | Resistance: 70.57 · 71.95 · 73.79
MO shows a technically healthy recovery from the July 30 gap-down crash, with the long-term uptrend intact above the rising 200 SMA ($65.00) and a fresh bullish MACD crossover confirming underlying momentum. Price is currently at $69.56, sitting between the 10 EMA ($68.35) and the 50 SMA ($69.97) — a classic "recovering trend" position approaching immediate resistance at the Bollinger upper band ($70.57). The analyst rates the stock HOLD, preferring to accumulate on weakness toward $66.98–$68.35 rather than chase the breakout, with stops placed at the critical $65.00 level (200 SMA).
Market Capitalization
$116.03 billion
TTM EPS
$4.75
P/E (TTM)
14.63x
Forward P/E
11.85x
PEG Ratio
2.67
Price/Book
-43.49x
Dividend Yield
6.38%
Beta
0.495
52-Week High
$77.06
52-Week Low
$54.70
50-Day Moving Average
$69.97
200-Day Moving Average
$66.28
Revenue (FY2025)
$20,139 million
Revenue (FY2024)
$20,444 million
Gross Profit (FY2025)
$14,542 million
Operating Income (normalized FY2025)
$12,035 million
Net Income (FY2025)
$6,947 million
Diluted EPS (FY2025)
$4.12
Net Income (FY2024)
$11,264 million
Diluted EPS (FY2024)
$6.54
Normalized EBITDA (TTM)
$12.97 billion
Profit Margin
39.0%
Operating Margin
61.5%
Gross Margin
87.2%
Return on Assets (ROA)
29.5%
Total Debt (Q2 2026)
$24,577 million
Long-Term Debt (Q2 2026)
$22,893 million
Net Debt (Q2 2026)
$22,210 million
Cash (Q2 2026)
$2,367 million
Stockholders' Equity (Q2 2026)
($2,668) million
AB InBev Stake
$8.90 billion
Net Debt / EBITDA
~1.7x
Operating Cash Flow (TTM)
$9.31 billion
Free Cash Flow (TTM)
$9.04 billion
FCF Yield
7.8%
CapEx (TTM)
$0.27 billion
Cash Dividends Paid (TTM)
$7.07 billion
Annualized Dividend per Share
$4.24/share
Dividend Payout Ratio (FCF)
79%
Dividend Payout Ratio (Net Income)
89%
Share Count (Q2 2026)
1,670 million
Share Count (2022)
1,804 million
Share Count (FY2025)
1,683 million
Buybacks (H1 2026)
$335 million
Dividends Paid (H1 2026)
$3.56 billion
Forward EPS Estimate
$5.86
Interest Expense (annual)
$1.18 billion
Tangible Book Value (Q2 2026)
($20,305) million
Goodwill & Intangibles (Q2 2026)
$17,637 million
Revenue (Q2 2026)
$5,356 million
Net Income (Q2 2026)
$2,298 million
Diluted EPS (Q2 2026)
$1.37
Normalized EBITDA (Q2 2026)
$3,301 million
Strengths
Concerns
Altria Group is a mature tobacco giant generating ~$9B in annual free cash flow with exceptional profitability metrics (39% net margin, 87% gross margin, 29.5% ROA) and a well-covered 6.38% dividend yield, trading at a moderate 11.85x forward P/E. The investment case centers on defensive cash flows, pricing power that offsets secular cigarette volume declines, and hidden value in the AB InBev stake, though the company faces structural headwinds from a shrinking combustible tobacco market, regulatory pressure, $24.6B in debt, and negative book equity from aggressive buybacks.
Macro: Fed rate-cut expectations: Polymarket shows 89% probability of ZERO Fed rate cuts in 2026 (up 0.4 pp). US recession odds: 7% (down 1.5 pp). Classic \"stay long quality yield\" regime — supportive for defensive yield names like MO. FRED macro data unavailable (API key not configured); no values fabricated.